ANZUP, Level 8, Health Translation Hub, 55 Botany Street, Sydney (2025)

12/08/2025

“At 44, I was fit, healthy, and living a great life… then came my stage 4 prostate cancer diagnosis.”

Sydney dad of two, Tim Weale, was living his dream, travelling Australia with his family when subtle symptoms signalled something wasn’t right.

At first, he brushed off changes to his urination and unexpected aches and pains. But soon after, tests revealed an aggressive prostate cancer that had already spread to his bones and lungs.

Since his 2023 diagnosis, Tim has faced hormone therapy, radiation, and chemotherapy with incredible courage - all while continuing to work, make memories with his family, and stay positive. Thanks to treatment, his PSA levels have dropped from 154 to 0.01. 🙌

His journey is a powerful reminder to listen to your body, get checked, and live every moment fully.

👉 Learn more about how ANZUP supports research into prostate cancer: https://ow.ly/AZa550WEcpO

07/08/2025

Testicular cancer is rare but primarily affects young people aged 15-45. Around 95% of people will survive at least five years after their initial diagnosis.

Treatments for testicular cancer are highly effective for most people affected, but sometimes these treatments can lead to challenges like fatigue, muscle loss, reduced s*x drive, anxiety and effects on body image. That's why ANZUP is committed to advancing research to improve both survival and quality of life for those affected.

🔬 Our current clinical trials include:

CLIMATE: Investigating a new blood test (miR-371a-3p) to detect residual disease after surgery, aiming to better personalise the management of disease.

P3BEP: Comparing accelerated versus standard chemotherapy schedules to enhance outcomes for patients with advanced germ cell tumors.

TIGER: Evaluating high-dose chemotherapy and stem cell transplant for relapsed or refractory germ cell tumors.

👉 Learn more about our testicular cancer trials: https://anzup.org.au/clinical-trials/testicular-cancer-trials/

30/07/2025

📢 Just published in The Lancet Oncology!

Predictive and prognostic value of baseline PSMA-PET total tumor volume (TTV) and SUVmean within a randomised phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)

Earlier this year, the ENZA-p trial received global recognition for showing that combining LuPSMA with enzalutamide helps people with high-risk metastatic castrate resistant prostate cancer live longer, better lives.

In this sub-study, Prof Louise Emmett and team show that PSMA-PET total tumour volume is
✅ Prognostic of overall survival with enzalutamide alone
✅ Predictive of improved overall survival with the addition of LuPSMA to enzalutamide

PSMA SUVmean was not predictive or prognostic for progression free or overall survival when LuPSMA is administered with enzalutamide.

These findings provide valuable insight into how PSMA-PET imaging can be used for predicting response to therapy.

Congratulations to Prof Emmett and the team on another globally recognised contribution to prostate cancer research! 🎉

🔗 Find out more here: https://ow.ly/4kVN50WxIFA

11/07/2025

You’ve heard of clinical trials, but what do they actually involve?

Swipe through this quick Q&A to learn:
✔️ What clinical trials are
✔️ Why they matter
✔️ Who can take part
✔️ What it’s like to join one

Got more questions? Drop them in the comments below! ⬇️

07/07/2025

📣 The ANZUP 2024/25 Annual Report is now available.

This year’s report is a powerful reflection of the impact we’ve made together in advancing GU cancer research and care.

Inside, you’ll find:
• Key research milestones
• Insights from our Chair and CEO
• Subcommittee highlights across Below the Belt cancers
• Membership educational events that brought our membership together
• Grants and awards that are fuelling the next wave of innovation
• A snapshot of our financial performance

📖 Read the full report: https://ow.ly/8ENK50Wlqz5

26/06/2025

Pe**le cancer is rare - but that doesn’t mean it’s not worth talking about.

Know the signs. Start the conversation.
And if you want to wear your support with pride (and a little cheek), grab a pair of ANZUP’s iconic socks 🍌🧦

👉 Swipe through to learn more about pe**le cancer
👀 Find out more about the Australian Pe**le Cancer Registry
🔗 https://ow.ly/2jnj50WguKj

**leCancer

19/06/2025

Today is World Kidney Cancer Day. 🫶

Kidney cancer is the 7th most diagnosed cancer in Australia. In 2024, around 4,700 people were diagnosed, and approximately 41,144 Australians were already living with the disease.

It most often affects adults over 45, but it can affect people of any age. Renal cell carcinoma, the most frequent kind of kidney cancer, makes up over more than 90% of adult kidney cancers.

🧠🩺 Kidney health is not only important for physical and mental wellbeing, but poor kidney function also affects quality of life.

This year, show your kidneys some love ❤️
Ask your doctor about three essential kidney tests to help stay on top of your health.

Learn more at worldkidneycancerday.org

12/06/2025

🚨 Big news in bladder cancer research!

An ANZUP-led trial has found a new way to treat high-risk bladder cancer and stretch global drug supplies, thanks to a powerful treatment combo.

The gold-standard treatment, Bacillus Calmette-Guérin (BCG), has faced global shortages since 2013. But new findings show that adding chemotherapy drug mitomycin to BCG therapy is a safe, effective alternative to BCG alone.

“Adding mitomycin means patients require 40% less BCG,” said lead researcher Professor Dickon Hayne. “This could offer a simple, cost-effective treatment option for people with bladder cancer.”

People in the trial also completed treatment more often, suggesting the combination was better tolerated than BCG alone.

👀 You can read Jack’s story here https://ow.ly/BKel50W86F7

Or if you'd like to help back the next big thing in cancer research, you can make a donation at anzup.org/donate-tax-time

03/06/2025

This tax time, your gift can help change the future for the 113 people in Australia and New Zealand diagnosed with Below the Belt cancers every day.

By supporting critical research, you're helping build a future where no one has to face these cancers with fear.

Donate before June 30 to make your impact count.

You can donate at: anzup.org.au/donate-tax-time, or by Facebook, below.

29/05/2025

🖤💛❤️ National Reconciliation Week 2025
Theme: Bridging Now to Next

This week, ANZUP proudly joins communities across the country in recognising National Reconciliation Week and reflecting on this year’s theme: "Bridging Now to Next".

We stand in solidarity with First Nations peoples, reaffirming our commitment to listening, learning, and acting to support reconciliation and equity in everything we do.

In clinical research and cancer care, we know that real progress only happens when all voices are heard and all communities are included. We’re continuing to build research that respects culture, strengthens relationships, and helps close the gap in cancer outcomes.

Let’s keep walking together towards a future that’s fair and just, because reconciliation is everyone’s business, every day.

20/05/2025

Happy International Clinical Trials Day!

Today ANZUP recognises international clinical trials day and celebrates the essential role that clinical trials play in advancing medical knowledge and outcomes. ANZUP’s mission is to improve the lives of those affected by prostate, kidney, testicular, pe**le and bladder cancers towards our vision of living life without fear of cancer.

We do this by conducting world-class clinical trials and research and to date over 10,000 people have participated in 35 globally significant ANZUP led and collaborative clinical trials.

One of ANZUP’s largest international trials ENZAMET, tested whether adding a hormone therapy (enzalutamide) to standard-of-care prostate cancer treatment could improve outcomes for patients.

Results showed the addition of hormone gave people with advanced prostate cancer about a 30% better chance of survival compared to standard treatment alone.

The findings contributed to enzalutamide being added to the Pharmaceutical Benefits Scheme (PBS) in 2023 — an Australian Government program that subsidises the cost of prescription medicines. This has improved access to this life-saving treatment by making it more affordable for those who need it.

Help us keep pushing forward in the fight against Below the Belt cancer by making a tax-deductible donation today!
https://anzup.org.au/donate-tax-time/

19/05/2025

The Banana Sock is here to help you look good, feel good, and do good 🍌✨

These socks help fund life-changing research for Below the Belt cancers. Grab yours at 👉 sydneysockproject.com

💥

ANZUP

12/08/2025

07/08/2025

30/07/2025

11/07/2025

07/07/2025

26/06/2025

19/06/2025

12/06/2025

03/06/2025

29/05/2025

20/05/2025

19/05/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share